[1] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3] FENG R M, ZONG Y N, CAO S M, et al.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun (Lond), 2019, 39(1):22.
[4] ZENG H, CHEN W, ZHENG R, et al.Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567.
[5] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].肿瘤综合治疗电子杂志,2020,6(2):55-85.
[6] 广东省抗癌协会肝癌专业委员会,中山大学肿瘤防治中心肝胆科.肝癌多学科综合治疗团队建立——广东专家共识 (1)[J].中国实用外科杂志,2014,24(8):732-734.
[7] 广东省抗癌协会肝癌专业委员会,中山大学肿瘤防治中心肝胆科.肝癌多学科联合治疗策略与方法——广东专家共识(2)[J].中国实用外科杂志,2014,24(11):735-738.
[8] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南2020[M].北京:人民卫生出版社,2020.
[9] 荚卫东. 精准肝脏外科时代肝癌多学科治疗[J].实用肝脏病杂志,2015,18(2):120-123.
[10] 中华医学会外科学分会肝脏外科学组.肝细胞癌外科治疗方法的选择专家共识(2016年第3次修订)[J].中华消化外科杂志,2017,16(2):113-115.
[11] OMATA M, CHENG A L, KOKUDO N, et al.Asia-Pacific clinical practice guidelines on the management of hepato-cellular carcinoma:a 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370.
[12] CHEN M S, LI J Q, ZHENG Y, et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006, 243(3):321-328.
[13] FENG K, YAN J, LI X, et al.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol, 2012, 57(4):794-802.
[14] XU Q, KOBAYASHI S, YE X, et al.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients[J]. Sci Rep, 2014, 4:7252.
[15] PENG Z W, LIN X J, ZHANG Y J, et al.Radiofrequency ablation versus hepatic resection for the treatment of hepato-cellular carcinomas 2 cm or smaller:a retrospective comp-arative study[J]. Radiology, 2012,262(3):1022-1033.
[16] LIVRAGHI T, MELONI F, DI STASI M, et al.Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?[J]. Hepatology, 2008, 47(1):82-89.
[17] PENG Z W, ZHANG Y J, CHEN M S, et al.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma:a prospective randomized trial[J]. J Clin Oncol, 2013, 31(4):426-432.
[18] PAN Y X, XI M, FU Y Z, et al. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study[J]. Cancers (Basel), 2019, 11(8). pii:E1116.
[19] 赵明,王健鹏,吴沛宏,等.TACE与TACE联合RFA治疗中晚期原发性肝癌167例临床对比分析[J].中华医学杂志,2010,90(41):2916-2921.
[20] 陈奇峰,贾振宇,杨正强,等.肝动脉化疗栓塞联合微波消融与单独肝动脉化疗栓塞治疗大肝癌疗效meta分析[J].介入放射学杂志,2017,26(3):225-231.
[21] WEI W, JIAN P E, LI S H, et al.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety[J]. Cancer Commun, 2018, 38(1):61.
[22] LI S, MEI J, WANG Q, et al. Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a PhaseⅢ, Randomized Controlled Clinical Trial[J]. Ann Surg Oncol, 2020. Online ahead of print .
[23] WANG Z, PENG Y, HU J, et al.Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients[J]. Ann Surg, 2020, 271(3):534-541.
[24] LU L, ZENG J, WEN Z, et al. Transcatheter arterial chemo-embolisation followed by three-dimensional conformal radio-therapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults[J]. Cochrane Database Syst Rev, 2019, 2(2):CD012244.
[25] YIN L, LI H, LI A J, et al.Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepato-cellular carcinoma beyond Milan Criteria: a RCT[J]. J Hepatol, 2014, 61(1):82-88.
[26] ZHONG J H, KE Y, GONG W F, et al.Hepatic resection associated with good survival for selected patients with inter-mediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2):329-340.
[27] CHEN W, MA T, ZHANG J, et al.A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma[J]. HPB (Oxford), 2020, 22(6):795-808.
[28] WANG Z, REN Z, CHEN Y, et al.Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcin-oma After Resection:A Randomized Controlled Study[J]. Clin Cancer Res, 2018, 24(9):2074-2081.
[29] ZHOU C, PENG Y, ZHOU K, et al.Surgical resection plus radiofrequency ablation for the treatment of multifocal hepato-cellular carcinoma[J]. Hepatobiliary Surg Nutr, 2019, 8(1):19-28.
[30] ZHANG Y, HUANG G, WANG Y, et al.Is Salvage Liver Rese ction Necessary for Initially Unresectable Hepatocellular Carci noma Patients Downstaged by Transarterial Chem-oembolization? Ten Years of Experience[J]. Oncologist, 2016, 21(12):1442-1449.
[31] 中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J].介入放射学杂志,2018,27(12):1117-1126.
[32] CHEN Q W, YING H F, GAO S, et al.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2016, 40(3):309-314.
[33] KUDO M.A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE[J]. Liver Cancer, 2019, 8(5):299-311.
[34] SHUQUN C, MENGCHAO W, HAN C, et al.Tumor thrombus types inflfluence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007, 54(74):499-502.
[35] XUE T C, XIE X Y, ZHANG L, et al.Transarterial chemoem-bolization for hepatocellular carcinoma with portal vein tumor thrombus:a meta-analysis[J]. BMC Gastroenterol, 2013, 13:60.
[36] HE M, LI Q, ZOU R, et al.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5(7):953-960.
[37] CHOI J H, CHUNG W J, BAE S H, et al.Randomized, prosp-ective, comparative study on the effffects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thro-mbosis[J]. Cancer Chemother Pharmacol, 2018, 82(3):469-478.
[38] PENG Z W, GUO R P, ZHANG Y J, et al.Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer, 2012, 118(19):4725-4736.
[39] SHI J, LAI EC, LI N, et al.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17(8):2073-2080.
[40] 中华医学会放射肿瘤学分会,中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会,中国研究型医院学会放射肿瘤学分会肝癌学组.2016年原发性肝癌放疗共识[J].中华放射肿瘤学杂志,2016,25(11): 1141-1150.
[41] SUN J, YANG L, SHI J, et al.Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus:An open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140:20-25.
[42] CHENG S, CHEN M, CAI J, et al.Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepato-cellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)[J]. Liver Cancer, 2020, 9(1):28-40.
[43] 广东省抗癌协会肝癌专业委员会,广东省医学会肝胆胰外科学分会.肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识(2015版)[J].中华消化外科杂志,2015,14(9):694-701.
[44] ZHU K, CHEN J, LAI L, et al.Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study[J]. Radiology, 2014, 272(1):284-293.
[45] WEI X, JIANG Y, ZHANG X, et al.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus:A Randomized, Open-Label, Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24):2141-2151.
[46] PENG B G, HE Q, LI J P, et al.Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009, 198(3):313-318.
[47] ZHANG Y F, GUO R P, ZOU R H, et al.Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study[J]. Eur Radiol, 2016, 26(7):2078-2088.
[48] LYU N, KONG Y, PAN T, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil,Leucovorin in Hepatocellular Cancer with Extrahepatic Spread[J]. J Vasc Interv Radiol, 2019, 30(3):349-357.e2.
[49] ZHANG H G, SUN J, CHEN Y X, et al.Image-guided IMRT improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma[J]. Ann Palliat Med, 2019, 8(5):717-727.
[50] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].中华肝脏病杂志,2017,25(9):664-677.
[51] 中华医学会肝病学分会,中华医学会消化病学分会.终末期肝病临床营养指南[J].中华肝脏病杂志,2019,27(5):330-342.
[52] 中华人民共和国国家卫生健康委员会.癌症疼痛诊疗规范 (2018年版)[J].临床肿瘤学杂志,2018,23(10):937-944.
[53] YAO F Y, FERRELL L, BASS N M, et al.Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modifified TNM criteria[J]. Liver Transpl, 2002, 8(9):765-774.
[54] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].中国医学前沿杂志(电子版),2019,11(12):51-77. |
